

**Characterization of antifungal compounds isolated from
Combretum and *Terminalia* species (Combretaceae)**

By

Peter Masoko

B.Sc (Med. Sci) (UNIN), M.Sc (Microbiology) (UNIN)

Submitted in fulfillment of the requirements for the degree

PHILOSOPHIAE DOCTOR (PhD)

In the

Faculty of Veterinary Science
Department of Paraclinical Science
Phytomedicine Programme

At the

UNIVERSITY OF PRETORIA

SUPERVISOR: Prof J.N. Eloff
CO-SUPERVISOR: Dr J.A. Picard

Pretoria
August 2006

DECLARATION

I, **PETER MASOKO**, hereby do declare that this thesis submitted for the award of the degree of **PHILOSOPHIAE DOCTOR (PhD)** of University of Pretoria is my independent work and it has previously not been submitted for a degree or any other examination at this of any other university.

Peter Masoko

_____ day of _____ 2006

DEDICATION

This work is dedicated first of all, to my parents who were my first teachers, my younger brothers Kegomoditswe, Kabelo, Mojalefa and sister Refilwe. Secondly my grandmother Mosepele Shongwane and my late uncle Mosalagae.

ACKNOWLEDGEMENTS

This study has been a long journey that would not have been successfully made if it were for the support of various persons.

First and foremost, I would like to acknowledge the support, guidance and encouragement of my supervisor, **Prof Jacobus N. Eloff**. Without your positive comments and persistent encouragement this work would have simply floundered on and on. I truly want to thank him for listening to my frustrated rantings and bringing me back to a relative level of clarity and calm. For allowing me to disrupt his precious moments at anytime during his busy work.

This also goes to, **Dr Jackie A. Picard**, my co-supervisor, for the constructive criticism, advices, and patience during the course of this research. Her encouragement and keen interest led to satisfactory realization of this study.

I would like to extend a sincere word of thanks to **Dr Lyndy McGaw** who did the proof-reading. Thank you for your willingness and the special effort in terms of timing.

My sincere thanks also goes to **Dr Ladislaus K. Mdee**, for helping with structure elucidation and chemical characterization.

Special thanks to **Dr Joshua Dabrowski** (Pathologist), for helping with histopathology studies.

My profound gratitude goes to **Mr Patrick N. Selahle** (Technologist), for helping with rats handling and technical assistance.

Ms Denise Marais, for continuous and rapid responses to my administrative questions and queries. Always with a smile.

Ms Lita Pauw, for making sure that all necessary equipments and materials are ordered. "Baie Dankie".

I am especially grateful to staff members of Bacteriology Section, Department of Tropical Diseases, University of Pretoria Onderstepoort Biomedical Research Centre (UPBRC) and Division of Pathology, Department of Paraclinical Sciences.

Thank you to **Mr Mathebula** (University of Limpopo, Medunsa Campus) for NMR and **Mr Ian Voster** (University of Johannesburg) for mass spectrometry.

I also appreciate the love and care my friends provided throughout this period. So everyone of you, especially to you **Calvin, Molatelo, Lerato** and **Moloisi**.

To all persons who helped me in one way or another during this work and whom I have not mentioned by nonetheless, I sincerely extend my thanks.

This study has been made possible by the financial support of **National Research Foundation (NRF)**, **Department of Agriculture (SA)** and **University of Pretoria**.

Last, but far from least, I am thankful to all my family members, particularly to my parents **Johannes Motheo** (father), **Johanna Mmakepi** (mother), who have been there for me throughout my student life and for their never-ending motivation, encouragement, unreserved support and love in realizing my dreams come true.

Lastly, I would like to appreciate and to give praise to **God Almighty** for grace, wisdom and comfort throughout the time of study. Glory be to God for indeed thus far has He brought me.

“The light shines in the darkness and the darkness has never put it out” John 1.5

CONFERENCES AND PROCEEDINGS

Paper Presentation

Masoko P., Picard J. and Eloff J.N., (2004). Screening of twenty-four South African *Combretum* species (Combretaceae) for antifungal activities. *Indigenous plant use forum (IPUF) (Clanwilliam)*.

Masoko P., Picard J. and Eloff J.N., (2004). Screening of twenty-four South African *Combretum* species (Combretaceae) for antifungal activities. Faculty Day, (*Faculty of Veterinary Science, University of Pretoria*)

Masoko P. and Eloff J.N., (2005). The diversity of antifungal compounds of six South African *Terminalia* species ((Combretaceae) determined by bioautography. *Indigenous plant use forum (IPUF) (Grahamstown)*.

Masoko P. and Eloff J.N., (2005). The diversity of antifungal compounds of six South African *Terminalia* species ((Combretaceae) determined by bioautography. *Faculty Day, (Faculty of Veterinary Science, University of Pretoria)*.

Masoko P., Picard J. and Eloff J.N. (2006). *In vivo* antifungal activity of *Combretum* and *Terminalia* extracts in rats. *Indigenous plant use forum (IPUF) (Gaborone, Botswana)*.

Poster Presentation

Masoko P., Picard J. and Eloff J.N., (2003). Screening of antifungal activity from medicinal plants (Combretaceae). *Indigenous plant use forum (IPUF) (Rustenburg)*.

Masoko P., Picard J. and Eloff J.N., (2003). Screening of antifungal activity from medicinal plants (Combretaceae). *Faculty Day, (Faculty of Veterinary Science, University of Pretoria)*.

Masoko P., Picard J. and Eloff J.N., (2005). Extracts of 30 South African *Combretum* and *Terminalia* species have antifungal activities with MIC's as low as 20 µg/ml. *53rd Annual meeting of Society Medicinal Plant Research (GA) (Florence, Italy)*.

MANUSCRIPTS PUBLISHED AND SUBMITTED

Masoko P., Picard J. and Eloff J.N., (2005). Screening of antifungal activity of six South African *Terminalia* species (Combretaceae). *Journal of Ethnopharmacology*, **99**. 301- 308.

Masoko P. and Eloff J.N., (2005). The diversity of antifungal compounds of six South African *Terminalia* species ((Combretaceae) determined by bioautography. *African Journal of Biotechnology*, **4(12)**, 1425-1431.

Masoko P. and Eloff J.N., (2006). Bioautography indicates the multiplicity of antifungal compounds from twenty-four South African *Combretum* species (Combretaceae). *African Journal of Biotechnology*, **5 (18)**, 1625 - 1647.

Masoko P., Picard J. and Eloff J.N., (2006). Antifungal activity of twenty-four South Africa *Combretum* species (Combretaceae) (*In Press: South African Journal of Botany*).

Masoko P., and Eloff J.N., (2006). Antioxidant activity of six *Terminalia* and twenty-four *Combretum* species found in South Africa (*In Press, Afr. J. Trad. CAM*).

Masoko P. Picard J. and Eloff J.N., (2006). Evaluation of the wound healing activity of selected *Combretum* and *Terminalia* species (Combretaceae) (*In Press, Onderstepoort Journal of Veterinary Research*).

Masoko P., Mdee L.K. and Eloff J.N., (2006). Biological activity of two related triterpenes isolated from *Combretum nelsonii* (Combretaceae) leaves (*Prepared for J. of Ethnopharmacology*).

Eloff J.N. and **Masoko P.**, (2006). Resistance of fungal pathogens to solvents used in bioassays. (*Prepared for South African Journal of Botany*).

Most of the chapters in this thesis have been written in the form of a manuscript for publication and will be submitted.

LIST OF ABBREVIATIONS

AIDS	Acquired immunodeficiency syndrome
ATCC	American type culture collection
BEA	Benzene/Ethanol/Ammonium hydroxide (90/10/1 v/v/v)
C ₁₈ column	18-Carbon reverse phase silica gel column
CEF	Chloroform/Ethylacetate/Formic acid (5/4/1 v/v/v)
CsA	Cycosporin A
DEPT	Distortionless enhancement by polarization transfer
DAC	Dicationic aromatic compounds
DCM	Dichloromethane
dH ₂ O	Distilled water
DMSO	Dimethylsulphoxide
DNA	Deoxyribose nucleic acid
DPPH	2, 2,diphenyl-1-picrylhydrazyl
EF3	Elongation factor
ELISA	Enzyme linked immunosorbent assay
EMW	Ethylacetate/Methanol/Water (40/5.4/4 v/v/v)
GGT	Geranylgeranyltransferase
GS	Glucan synthase
HMBC	Heteronuclear multiple bond correlation
HMQC	Heteronuclear multiple quantum coherence
HPLC	High performance liquid chromatography
INT	Iodonitro-tetrazolium salts
LC ₅₀	Lethal concentration for 50% of the cells
LPO	Lactoperoxidase
LNBG	Lowveld National Botanical Garden
MIC	Minimum inhibitory concentration
MS	Mass spectrometry
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye
NaCl	Sodium chloride
NADH	Nicotinamide Adenine Dinucleotide
NADPH	Nicotinamide Adenine Dinucleotide Phosphate
NCCLS	National Committee for Clinical Laboratory Standards
NMR (¹³ C and ¹ H)	Nuclear magnetic resonance (carbon 13 and proton)
PBS	Phosphate buffer saline
R _f	Retardation factor

rpm	revolutions per minute
SEE	Serial exhaustive extraction
TLC	Thin layer chromatography
UP	University of Pretoria
UV	Ultra violet radiation
v/v	volume per volume
VLC	Vacuum liquid chromatography
WHO	World Health Organisation

SUMMARY

Several investigations into the antimicrobial activity of members of the Combretaceae have been undertaken in recent years. Although the antibacterial properties of various species of *Combretum*, *Terminalia* and *Pteleopsis* have been investigated in depth, this is not the case for their antifungal properties. Due to the increasing importance of fungal infections the aim is to address this by focusing on antifungal activities of Combretaceae species. This was done by focusing on the following objectives:

1. Developing minimum inhibitory concentration (MIC) and bioautography procedures for fungi to be used in the laboratory in order to screen *Combretum* and *Terminalia* species for antifungal activity.
2. Selecting three or four species for further investigation based on antifungal activity and availability.
3. Isolating the antifungal compounds from one or more of the selected species.
4. Determining the chemical structure and *in vitro* biological activity of the antifungal compound.
5. Developing and applying a protocol and determining *in vivo* antifungal activity of *Combretum* and *Terminalia* extracts and isolated compounds in rats infected with different fungal pathogens.

Leaves of 24 *Combretum* and 6 *Terminalia* species were collected in the Lowveld National Botanical Gardens (LNBG) in Nelspruit. After the dried plants were milled to a fine powder, they were extracted with hexane, dichloromethane, acetone and methanol. Chemical constituents of the 120 extracts were analyzed by thin layer chromatography (TLC). The TLC plates were developed with one of the three eluent systems developed in our laboratory that separate components of Combretaceae extracts well i.e.: Ethyl acetate/methanol/water (40:5.4:5) [EMW] (polar/neutral), Chloroform/ethyl acetate/formic acid (5:4:1) [CEF] (intermediate polarity/acidic) and Benzene/ethanol/ammonia hydroxide (90:10:1) [BEA] (non-polar/basic). To detect the separated compounds, vanillin-sulphuric acid-methanol was sprayed on the chromatograms and heated at 110 °C to optimal colour development. Methanol was the best extractant, extracting a greater quantity of plant material than any of the other solvents. There was similarity in the chemical composition of the non-polar compounds of extracts using extractants of varying polarity

Qualitative analysis of antioxidant activity, the 2, 2-diphenyl-1-picrylhydrazyl (DPPH) assay on TLC plates was used as a screen test for the radical scavenging ability of the compounds present in the different 120 extracts. TLC-DPPH screening method indicated the presence of

antioxidant compounds in some of the extracts tested, with *C. woodii* and *C. hereroense* showing the most prominent antioxidant activity. Methanol and acetone extracted the most antioxidant compounds based on DPPH TLC. *In vitro* studies coupled with the phytochemical analysis confirm that the extracts had antioxidant activity.

The solvent tolerance of the microorganisms was tested using the following solvents; DMSO, acetone, methanol and ethanol. In order to determine the maximum concentration at which different solvents would allow the test microorganisms to reach normal growth, different concentrations from 10 to 100% were used. Uninhibited growth was evaluated as no toxic effects of the solvent. Methanol and ethanol were found to be toxic. The growths of the fungi were not affected by DMSO and acetone concentrations up to 60%.

A serial microdilution assay was used to determine the minimum inhibitory concentration (MIC) values for plant extracts using tetrazolium violet reduction as an indicator of growth. This method had previously been used only for antibacterial activities. To apply it to measuring antifungal activities, a slight modification was made to suit fungal growth conditions. The following fungal pathogens were used: yeasts (*Candida albicans* and *Cryptococcus neoformans*), thermally dimorphic fungi (*Sporothrix schenckii*) and moulds (*Aspergillus fumigatus* and *Microsporum canis*). To determine MIC values, growth was checked after 24 and 48 hours to determine the end point. The MIC values of most of the extracts were in the order of 0.08 mg/ml and some had values as low as 0.02 – 0.04 mg/ml after 24 hours incubation.

TLC plates were loaded with 100 µg (5 µl of 20 mg/ml) of each of the extracts. The prepared plates were developed in the three different mobile systems used: CEF, BEA and EMW. The chromatograms were dried for a week at room temperature under a stream of air to remove the remaining solvent. The TLC plates developed were inoculated with a fine spray of the concentrated suspension containing approximately 10⁹ organisms per ml of actively growing fungi e.g. conidia for *A. fumigatus* and yeast cells (blastocysts) for the other fungi in a Biosafety Class II cabinet (Labotec, SA) cupboard. The plates were sprayed until they were just wet, and after drying were sprayed with a 2 mg/ml solution of INT. White areas indicate where reduction of INT to the coloured formazan did not take place due to the presence of compounds that inhibited the growth of tested fungi.

During this study we experienced a number of difficulties. Firstly I found that preparing cultures some days before spraying them makes it difficult to get good results, possibly due to quick mycelial overgrowth and blockage of the spray gun with mycelia. The new method

was developed. This procedure led to reduced overgrowth of the mycelia. In the study of biologically active compounds from extracts, it was indicated that the extracts had antifungal compounds.

Fractionation and bioassay-guided isolation of the antifungal compounds was undertaken on the crude extracts of *C. nelsonii*, based on very low MIC's of the crude extracts on all tested pathogens, it had several compound which are active against all pathogens, lastly it is one of the *Combretum* species which have never being worked on. Antifungal compound was successfully isolated from the leaves of *C. nelsonii*. The structure was elucidated.

After structure elucidation bioassays of isolated active compounds was done to confirm that the compound isolated is the one expected, and how active the compound is, on its own. The compound was very active against all tested pathogens.

Cytotoxicity of the acetone extracts of *C. imberbe*, *C. nelsonii*, *C. albopunctatum* and *T. sericea* were evaluated using Brine shrimp (*Artemia salina*) assay and tetrazolium-based colorimetric assay (MTT assay) on Vero monkey kidney cells. These four extracts were chosen because of the good *in vitro* antifungal activity of crude extracts and there was intention of using them in *in vivo* studies in animal models. The results on brine shrimps indicated that the four leaf extracts have LC₅₀ values above 20 µg/ml, the recommended cut-off point for detecting cytotoxic activity. Using MTT assay it was found that the four extracts did not suppress mitochondrial respiration in monkey kidney cells. Only *C. imberbe* was closer to the cut-off value (200 µg/ml), which was used by other authors. In searching for cytotoxic activity to the criteria of the American National Cancer Institute, the LC₅₀ limit to consider a crude extract promising for further purification is lower than 30 µg/ml.

In vivo antifungal activity was investigated on the wound irritancy and efficacy of the four most promising, *Combretum nelsonii*, *Combretum imberbe*, *Combretum albopunctatum* and *Terminalia sericea* extracts applied topically to skin wounds in fungal infected skin wound of rat model. Wound irritancy and wound healing were evaluated by macroscopical, physical and histological methods. Aspects evaluated include wound healing, erythema, exudate formation and possible toxic effects of the extracts. Twenty rats were used in two pilot studies (Exploratory studies and Infection with different pathogens). During the pilot studies rats were not irritated by treatment of infection. The wound healed within three weeks. Only one rat was terminated due to weight loss and it was found that nasal discharge was due to external factors, which were not related to the experiment.

The clinical treatment of skin infected with pathogens continues to be a major problem especially in immuno-compromised patients. Therapeutic agents selected for the treatment of infected wounds had ideally shown antifungal activity on *in vitro* studies. I investigated whether these agents would improve phases of wound healing without producing deleterious side effects. All the parameters showed that the crude extracts and amphotericin B were effective in decreasing formation of the exudate, increasing crust formation and that they have antifungal activities used in *in vivo* studies. Acetone extract of leaves of *C. nelsonii*, *C. albopunctatum*, *C. imberbe* and *T. sericea* possessed remarkable growth inhibitory activities against fungal pathogens. Acetone extracts of leaves and isolated compound demonstrated wound healing properties comparable with that of antibiotic powder (amphotericin B).

The results of this study in general indicate that the *Terminalia* and *Combretum* species possess substantial antifungal properties. This explains the use of these plants in folk medicine for the treatment of various diseases related to fungal infections.

TABLE OF CONTENTS

DECLARATION	ii
DEDICATION	iii
ACKNOWLEDGEMENTS	iv
CONFERENCES AND PROCEEDINGS	vi
MANUSCRIPTS PUBLISHED AND PREPARED	vii
LIST OF ABBREVIATIONS	viii
SUMMARY	x
LIST OF FIGURES	xxi
LIST OF TABLES	xxx
CHAPTER 1 Literature Review	1
1. Introduction	1
1.1 Medicinal plants	2
1.1.1. Approaches for selecting medicinal plants	3
1.1.2. Importance of medicinal plants	3
1.1.3. Traditional herbal medicine	4
1.1.4. Ethnobotanical research	5
1.1.4.1. Ethnological	5
1.1.4.2. Developing	5
1.1.4.3. Pharmaceutical	6
1.2. Combretaceae	6
1.2.1. Ethnopharmacology of Combretaceae	8
1.2.2. Antimicrobial activity of the Combretaceae	9
1.2.3. Phytochemistry of the Combretaceae	9
1.3. Some of the work done on Combretaceae family in Phytomedicine Programme	10
1.4. Existing antifungal drugs	14
1.4.1. Novel antifungal medicine	15
1.4.1.1. Inhibitors of fungal cell membranes	16
1.4.1.2. Inhibitors of fungal cell wall	17
1.4.1.3. Inhibitors of protein synthesis	18
1.4.1.4. N-myristoyltransferase inhibitors	18
1.5. New potential targets for antifungal development	18

1.5.1. The fungal cell wall	19
1.5.2. The fungal cytoplasmic membrane	21
1.5.3. DNA and protein synthesis	22
1.5.4. Signal transduction pathways	23
1.5.5. Virulence factors	23
1.6. Major groups of antimicrobial compounds from plants	24
1.6.1. Phenolics and Polyphenols	24
1.6.2. Quinones	25
1.6.3. Flavones, flavonoids, and flavonols	26
1.6.4. Tannins	27
1.6.5. Coumarins	27
1.6.6. Terpenoids and Essential Oils	28
1.6.7. Alkaloids	29
1.6.8. Lectins and Polypeptides	30
1.7. Fungi	30
1.7.1. Structure	30
1.7.1.1. Yeast	31
1.7.1.2. Moulds	31
1.7.1.3. Dimorphic fungi	32
1.7.2. Classification	32
1.7.2.1 Clinical classification of the mycoses	33
1.7.3. Multiplication	33
1.7.4. Pathogenesis	33
1.7.5. Host Defenses	34
1.7.6. Epidemiology	34
1.7.7. Diagnosis	35
1.7.8. Treatment	35
1.8. Fungal pathogens used in this study	37
1.8.1. <i>Candida albicans</i>	37
1.8.1.a. Pathogenicity and Clinical Significance	37
1.8.2. <i>Aspergillus fumigatus</i>	38
1.8.2.a. Pathogenicity and Clinical Significance	38
1.8.3. <i>Sporothrix schenckii</i>	39
1.8.3.a. Pathogenicity and Clinical Significance	39
1.8.4. <i>Cryptococcus neoformans</i>	40
1.8.4.a. Pathogenicity and Clinical Significance	40
1.8.6. <i>Microsporum canis</i>	41

1.8.6.a. Pathogenicity and Clinical Significance	41
1.9. Aim and Objectives	41
1.9.1. Hypothesis	41
CHAPTER 2 (Extraction and TLC profiles)	43
2.1. Introduction	43
2.1.1. Extraction	43
2.1.2. Choice of solvents	44
2.1.3. Solvent volume	44
2.1.4. Temperature	45
2.1.5. Extraction time	45
2.1.6. Analysis of compounds in extracts	45
2.2. Materials and Methods	46
2.2.1. Plant collection	46
2.2.2. Plant storage	48
2.2.3. Extractants	48
2.2.4. Extraction procedure	48
2.2.5. Phytochemical analysis	49
2.3. Results	49
2.3.1. Extraction of raw material	49
2.3.2. Phytochemical analysis	55
2.4. Discussion	58
CHAPTER 3 (Antioxidants)	61
3.1. Introduction	61
3.1.1. Antioxidant screening	62
3.2. Materials and Methods	63
3.2.1. TLC-DPPH antioxidant screening	63
3.3. Results and Discussion	64
3.4. Conclusion	70
CHAPTER 4 (Solvent toxicity)	71
4.1. Introduction	71
4.2. Materials and Method	71

4.2.1. Solvents used	71
4.2.2. Bioassays	72
4.3. Results	72
4.4. Discussion	76
4.5. Conclusion	78
CHAPTER 5 Antifungal assays (Minimum Inhibitory Concentration)	79
5.1. Introduction	79
5.1.1. <i>p</i> -iodonitrotetrazolium violet (INT) reaction	79
5.2. Materials and Method	80
5.2.1. Fungal test organisms	80
5.2.2. Minimum inhibitory concentration	80
5.2.2.1. Microdilution assay	80
5.2.2.2. The experimental design	81
5.3. Results (Papers)	82
5.3.1. Antifungal activities of six South African <i>Terminalia</i> species (Combretaceae). J. of Ethnopharmacology, 99, 301-308.	82
5.3.2. The antifungal activity of twenty-four South African <i>Combretum</i> species (Combretaceae) (<i>Submitted to SAJB</i>).	90
CHAPTER 6 (Bioautography)	111
6.1. Introduction	111
6.1.1. <i>Terminalia</i> paper	112
The diversity of antifungal compounds of six South African <i>Terminalia</i> species (Combretaceae) determined by bioautography. African Journal of Biotechnology, 4(12), 1425-1431.	112
6.1.2. <i>Combretum</i> paper	120
Bioautography indicates the multiplicity of antifungal compounds from twenty- four South African <i>Combretum</i> species (Combretaceae) (<i>In Press: African Journal of Biotechnology</i>).	120
CHAPTER 7 (Extraction and isolation of compounds)	
7.1. Introduction	155
7.2. Materials and methods	155

7.2.1. Extraction procedure	155
7.2.2. Analysis by TLC	156
7.2.3. Bioautography	156
7.2.4. Microdilution assay	156
7.2.5. Total activity	157
7.2.6. Isolation	157
7.2.6.1. Open column chromatography	157
7.2.6.2. Analysis and grouping of fractions	158
7.2.6.3. Combination of fractions	158
7.3. Results of Vacuum Liquid Chromatography	159
7.3.1. Extraction	159
7.3.2. Phytochemical analysis	159
7.3.3. Quantitative antifungal activity	160
7.3.4. Quantitative analysis of antifungal compounds	162
7.3.5. Fractionation of VLC fractions	164
7.4. Discussion and Conclusion	173
CHAPTER 8 (Structure elucidation)	176
8.1. Introduction	176
8.1.1. Nuclear Magnetic Resonance (NMR)	176
8.1.2. Mass spectrometry (MS)	177
8.1.3. Distortionless enhancement by polarization transfer (DEPT)	178
8.1.4. Heteronuclear multiple bond correlation (HMBC)	178
8.1.5. Heteronuclear multiple quantum coherence (HMQC)	178
8.1.6. Correlation Spectroscopy (COSY)	178
8.2. Materials and Methods	178
8.2.1. Nuclear Magnetic Resonance (NMR)	178
8.2.2. Mass spectrometry (MS)	179
8.3. Results	179
8.4. Discussion	184
CHAPTER 9 (In vitro cytotoxicity tests of the developed extracts and isolated compounds)	185
9.1. Introduction	185
9.1.1. The brine shrimp assay	186

9.1.2. The MTT cytotoxicity assay	186
9.2. Materials and Methods	187
9.2.1. Extracts selected	187
9.2.2. The brine shrimp assay	187
9.2.3. The MTT cytotoxicity assay	188
9.2.4. Statistics	189
9.3. Results	189
9.3.1. The brine shrimp assay	189
9.3.2. The MTT cytotoxicity assay	192
9.4. Discussion	197
9.5. Conclusion	200
Chapter 10 (Bioassays of isolated compounds)	201
10.1. Introduction	201
(Paper) Biological activity of two related triterpenes isolated from <i>Combretum nelsonii</i> (Combretaceae) leaves. (<i>Prepared for Journal of Ethnopharmacology</i>)	202
CHAPTER 11 (<i>In vivo</i> antifungal activity of <i>Combretum</i> and <i>Terminalia</i> extracts and isolated compounds in rats)	218
11.1. Introduction	218
11.1.1. Aim	218
11.1.2. Objective	219
11.2. Materials and methods	220
11.2.1. Selection of rats	220
11.2.2. Housing and feeding conditions	220
11.2.3. Preparation of animals	220
11.2.4. Wound creation	221
11.2.5. Induced fungal infections	221
11.2.6. Preparation of extracts	221
11.3. Exploratory studies	221
11.3.1. Pilot study I (Local irritancy and wound healing study)	221
11.3.2. Pilot study II (Infection with different pathogens)	222
11.3.3 Confirmation study	223
11.3.3.1. Treatment of different sites on individual rats	224
11.3.3.2. Administration of doses	225

11.3.3.3.Observations	225
11.3.3.4.Daily observations on weekdays	226
11.4. Evaluation of lesions	226
11.4.1. Lesion size measured	226
11.4.2. Other parameters of infection/recovery	226
11.5.Pathological and histopathological studies	226
11.6. Results	226
11.6.1. Paper. Evaluation of the wound healing activity of selected <i>Combretum</i> and <i>Terminalia</i> species (Combretaceae) (2006) (<i>submitted to Onderstepoort Journal of Veterinary Research</i>). (End of the Chapter)	
11.6.2. Pilot study II (Infection with different pathogens)	230
11.6.3. Confirmation study	243
11.7. Discussion	266
11.8. Conclusion	278
CHAPTER 12 (General Discussion and Conclusion)	298
CHAPTER 13 (References)	303
CHAPTER 14 (Appendix)	327

LIST OF FIGURES

Chapter 1		Page
Figure 1.1	Schematic view of emerging targets for antifungal drug development	19
Figure 1.2	Working model of glucan synthase	20
Figure 1.3	Caffeic acid	25
Figure 1.4	Eugenol	25
Figure 1.5	Quinone	25
Figure 1.6	Flavone	26
Figure 1.7	Tannins	27
Figure 1.8	Coumarins	28
Figure 1.9	Terpenoids	28
Figure 1.10	Berberine	29
 Chapter 2 		
Figure 2.1	Percentage of powdered <i>Terminalia</i> leaf samples extracted by acetone, hexane, dichloromethane and methanol from the six <i>Terminalia</i> species.	51
Figure 2.2	Percentage of powdered <i>Combretum</i> species leaf extracted by acetone, hexane, dichloromethane and methanol	53
Figure 2.3a	Chromatograms of <i>Terminalia</i> species developed in BEA (top), CEF (centre), and EMW (bottom) solvent systems and sprayed with vanillin–sulphuric acid to show compounds extracted with acetone (Ac), hexane (Hex), dichloromethane (D) and methanol (Met), in lanes from left to right for each group	55
Figure 2.3b	Chromatograms of <i>Combretum</i> species developed in BEA (top), CEF (centre), and EMW (bottom) solvent systems and sprayed with vanillin–sulphuric acid to show compounds extracted with acetone (Ac), hexane (Hex), dichloromethane (D) and methanol (Met), in lanes from left to right for each group	56
Figure 2.3c	Chromatograms of <i>Combretum</i> species developed in BEA (top), CEF (centre), and EMW (bottom) solvent systems and sprayed with vanillin–sulphuric acid to show compounds extracted with acetone (Ac), hexane (Hex), dichloromethane	57

(D) and methanol (Met), in lanes from left to right for each group

Chapter 3

- Figure 3.1** Reaction of DPPH with hydroxyl groups of free radical (R-OH) to produce 2-(4-hydroxyphenyl)-2-phenyl-1-picryl hydrazine and R-NO₂, 2-(4 nitrophenyl)-2phenyl-1-picrylhydrazine 63
- Figure 3.2a** Chromatograms of *Combretum* species developed in BEA (top), CEF (centre), and EMW (bottom) solvent systems and sprayed with 0.2% DPPH in methanol, clear zones indicate antioxidant activity of compounds extracted with acetone (Ac), hexane (Hex), dichloromethane (D) and methanol (Met), in lanes from left to right for each group 65
- Figure 3.2b** Chromatograms of *Combretum* species developed in BEA (top), CEF (centre), and EMW (bottom) solvent systems and sprayed with 0.2% DPPH in methanol, clear zones indicate antioxidant activity of compounds extracted with acetone (Ac), hexane (Hex), dichloromethane (D) and methanol (Met), in lanes from left to right for each group 66
- Figure 3.2c** Chromatograms of *Terminalia* species developed in BEA (top), CEF (centre), and EMW (bottom) solvent systems and sprayed with 0.2% DPPH in methanol, clear zones indicate antioxidant activity of compounds extracted with acetone (Ac), hexane (Hex), dichloromethane (D) and methanol (Met), in lanes from left to right for each group 67

Chapter 4

- Figure 4.1** Test tubes of 10 % to 100 % acetone from left to right for each group mixed with different fungi and 2 mg/ml of *p*-iodonitrotetrazolium violet (INT) as an indicator. Purple colours indicate fungal growth and clear tubes indicate no growth 73
- Figure 4.2** Effects of solvents on tested fungi 75
- Figure 4.3** Average MIC showing the effects of solvents on tested fungi 75
- Figure 4.4** Average MIC of solvents on tested fungi 76

Chapter 5

Minimum Inhibitory Concentration (Papers)

Chapter 6

Bioautography (Papers)

Chapter 7

Figure 7.1	Mass extracted by acetone, DCM, acetone, and methanol from <i>C. nelsonii</i>	160
Figure 7.2	Chromatograms of <i>C. nelsonii</i> extracts developed in BEA (top), CEF (centre), and EMW (bottom) solvent systems and sprayed with vanillin–sulphuric acid to show compounds extracted with acetone, DCM, hexane and methanol	161
Figure 7.3	Bioautography of <i>C. nelsonii</i> extracts separated by BEA (top), CEF (Centre) and EMW (Bottom) and sprayed with <i>C. albicans</i> (A) and <i>C. neoformans</i> (B). White areas indicate where reduction of INT to the coloured formazan did not take place due to the presence of compounds that inhibited the growth.	162
Figure 7.4	Bioautography of <i>C. nelsonii</i> extracts separated by BEA (top), CEF (Centre) and EMW (Bottom) and sprayed with <i>S. schenckii</i> (A), <i>A. fumigatus</i> (B) and <i>M. canis</i> (C). White areas indicate where reduction of INT to the coloured formazan did not take place due to the presence of compounds that inhibited the growth.	163
Figure 7.5	Chromatograms of <i>C. nelsonii</i> acetone extracts developed in CEF solvent systems and sprayed with vanillin–sulphuric acid to show compounds isolated with different eluent systems	165
Figure 7.6	Bioautography of <i>C. nelsonii</i> acetone extracts separated by CEF and sprayed with <i>C. albicans</i> . White areas indicate where reduction of INT to the coloured formazan did not take place due to the presence of compounds that inhibited the growth of <i>C. albicans</i>	165
Figure 7.7	Bioautography of <i>C. nelsonii</i> acetone extracts separated by CEF and sprayed with <i>M. canis</i> . White areas indicate where reduction of INT to the coloured formazan did not take place due to the presence of compounds that inhibited the growth of	166

	<i>M. canis</i>	
Figure 7.8	Bioautography of <i>C. nelsonii</i> acetone extracts separated by CEF and sprayed with <i>S. schenckii</i> . White areas indicate where reduction of INT to the coloured formazan did not take place due to the presence of compounds that inhibited the growth of <i>S. schenckii</i>	166
Figure 7.9	Bioautography of <i>C. nelsonii</i> acetone extracts separated by CEF and sprayed with <i>C. neoformans</i> . White areas indicate where reduction of INT to the coloured formazan did not take place due to the presence of compounds that inhibited the growth of <i>C. neoformans</i>	167
Figure 7.10	Chromatograms of <i>C. nelsonii</i> acetone extracts isolated with 90% ethyl acetate and developed in CEF solvent systems and sprayed with vanillin–sulphuric acid to show compounds isolated with different eluent systems	168
Figure 7.11	Overview of isolation process of four active compound	169
Figure 7.12	Chromatograms of <i>C. nelsonii</i> DCM extracts developed in CEF solvent systems and sprayed with vanillin–sulphuric acid to show compounds separated with different eluent systems	171
Figure 7.13	Bioautography of <i>C. nelsonii</i> DCM extracts separated by CEF and sprayed with <i>A. fumigatus</i> . White areas indicate where reduction of INT to the coloured formazan did not take place due to the presence of compounds that inhibited the growth of <i>A. fumigatus</i>	171
Figure 7.14	Bioautography of <i>C. nelsonii</i> DCM extracts separated by CEF and sprayed with <i>C. albicans</i> . White areas indicate where reduction of INT to the coloured formazan did not take place due to the presence of compounds that inhibited the growth of <i>C. albicans</i>	172
Figure 7.15	Bioautography of <i>C. nelsonii</i> DCM extracts separated by CEF and sprayed with <i>C. neoformans</i> . White areas indicate where reduction of INT to the coloured formazan did not take place due to the presence of compounds that inhibited the growth of <i>C. neoformans</i>	172
Figure 7.16	Bioautography of <i>C. nelsonii</i> DCM extracts separated by CEF and sprayed with <i>M. canis</i> . White areas indicate where reduction of INT to the coloured formazan did not take place	172

due to the presence of compounds that inhibited the growth of *M. canis*

- Figure 7.17** Bioautography of *C. nelsonii* DCM extracts separated by CEF and sprayed with *S. schenckii*. White areas indicate where reduction of INT to the coloured formazan did not take place due to the presence of compounds that inhibited the growth of *S. schenckii* 173
- Figure 7.18** Chromatograms of combined fractions of *C. nelsonii* DCM extracts isolated with 80% ethyl acetate and developed in CEF solvent systems and sprayed with vanillin–sulphuric acid to show compounds isolated. 173

Chapter 8

- Figure 8.1** ^{13}C NMR spectrum of **Compound I** 179
- Figure 8.2** ^1H NMR spectrum of **Compound I** 180
- Figure 8.3** HMBC NMR spectrum of **Compound I** 180
- Figure 8.4** HSQC NMR spectrum of **Compound I** 181
- Figure 8.5** gCOSY NMR spectrum of **Compound I** 181
- Figure 8.6** gHMBC NMR spectrum of **Compound I** 182
- Figure 8.7** gHSQC NMR spectrum of **Compound I** 182
- Figure 8.8** Terminolic acid 183
- Figure 8.9** Compound **1**, a mixture of two inseparable compounds, which were asiatic acid (**1b**) and arjunolic acid (**1a**) 183

Chapter 9

- Figure 9.1** Brine shrimp assay mortality after exposure to *C. nelsonii* extract 189
- Figure 9.2** Brine shrimp assay mortality after exposure to *C. imberbe* extract 190
- Figure 9.3** Brine shrimp assay mortality after exposure to *C. albopunctatum* extract 190
- Figure 9.4** Brine shrimp assay mortality after exposure to *T. sericea* extract 191
- Figure 9.5** Brine shrimp assay curve of Podophyllotoxin (Positive control) 191
- Figure 9.6** MTT cytotoxicity assay curve for Berberine chloride 192
- Figure 9.7** Percentage cell viability of berberine different concentration 193
- Figure 9.8** MTT cytotoxicity activity of *C. imberbe* extract against Vero 194

	cells	
Figure 9.9	MTT cytotoxicity activity of <i>C. nelsonii</i> extract against Vero cells	194
Figure 9.10	MTT cytotoxicity activity of <i>T. sericea</i> extract against Vero cells	195
Figure 9.11	MTT cytotoxicity activity of <i>C. albopunctatum</i> extract against Vero cells	195
Figure 9.12	LC ₅₀ of the tested extracts	196

Chapter 11

Figure 11.1	Wounds creation	227
Figure 11.2	Wound treating and dressing	228
Figure 11.3	Wound healing and necropsy	229
Figure 11.4 – 11.9	Wound healing Paper	
Figure 11.10a	Weights of rat 1 to rat 6 in pilot study 2	230
Figure 11.10b	Weights of rat 7 to rat 12 in pilot study 2	230
Figure 11.11a	Temperatures of rat 1 to rat 6 in pilot study 2	231
Figure 11.11b	Temperatures of rat 7 to rat 12 in pilot study 2	231
Figure 11.12a	The average lesion size of lesions infected with <i>C. albicans</i> and treated with four extracts and Amphotericin B (positive control).	232
Figure 11.12b	The average lesion size of lesions infected with <i>C. neoformans</i> and treated with four extracts and Amphotericin B (positive control).	232
Figure 11.12c	The average lesion size of lesions infected with <i>M. canis</i> and treated with four extracts and Amphotericin B (positive control).	233
Figure 11.12d	The average lesion size of lesions infected with <i>S. schenckii</i> and treated with four extracts and Amphotericin B (positive control).	233
Figure 11.13a	The influence of the crude extracts and Amphotericin B (positive control) on the wound erythema of rat in pilot study 2	234
Figure 11.13b	Average arbitrary values of erythema of rats in pilot study 2 with error bars	234
Figure 11.14a	The influence of the crude extracts and Amphotericin B	235

	(positive control) on the exudate formed of rats in pilot study 2.	
Figure 11.14b	Average arbitrary values of exudate of rats in pilot study 2 with error bars	235
Figure 11.15a	The influence of the crude extracts and Amphotericin B (positive control) on the crust formed of rats in pilot study 2	236
Figure 11.15b	Average arbitrary values of crust formation of rats in pilot study 2 with error bars	236
Figure 11.16a	Normal rat skin	237
Figure 11.16b	Fibrosis/Fibroplasia and Angiogenesis	237
Figure 11.16c	Fibrosis	238
Figure 11.16d	Degeneration of cells	238
Figure 11.16	Weights of rats (1 to 6) infected with <i>C. albicans</i> .	243
Figure 11.17	Weights of rats (7 to 12) infected with <i>C. neoformans</i> .	244
Figure 11.18	Weights of rats (13 to 18) infected with <i>M. canis</i> .	244
Figure 11.19	Weights of rats (19 to 24) infected with <i>S. schenckii</i> .	245
Figure 11.20	Temperatures of rats (1 to 6) infected with <i>C. albicans</i> .	246
Figure 11.21	Temperatures of rats (7 to 12) infected with <i>C. neoformans</i> .	246
Figure 11.22	Temperatures of rats (13 to 18) infected with <i>M. canis</i> .	247
Figure 11.23	Temperatures of rats (19 to 24) infected with <i>S. schenckii</i> .	247
Figure 11.24	The average lesion size of lesions infected with <i>C. albicans</i> and treated with four extracts, isolated compound and Amphotericin B (positive control).	248
Figure 11.25	The average lesion size of lesions infected with <i>C. neoformans</i> and treated with four extracts, isolated compound and Amphotericin B (positive control).	248
Figure 11.26	The average lesion size of lesions infected with <i>M. canis</i> and treated with four extracts, isolated compound and Amphotericin B (positive control).	249
Figure 11.27	The average lesion size of lesions infected with <i>S. schenckii</i> and treated with four extracts, isolated compound and Amphotericin B (positive control).	249
Figure 11.28a	The influence of the crude extracts, isolated compound and Amphotericin B (positive control) on the wound erythema of rat infected with <i>C. albicans</i> .	250
Figure 11.28b	Average arbitrary values of erythema of rats infected with	251

	<i>C. albicans</i> with error bars	
Figure 11.29a	The influence of the crude extracts, isolated compound and Amphotericin B (positive control) on the wound erythema of rat infected with <i>C. neoformans</i> .	251
Figure 11.29b	Average arbitrary values of erythema of rats infected with <i>C. neoformans</i> with error bars	252
Figure 11.30a	The influence of the crude extracts, isolated compound and Amphotericin B (positive control) on the wound erythema of rat infected with <i>M. canis</i> .	252
Figure 11.30b	Average arbitrary values of erythema of rats infected with <i>M. canis</i> with error bars	253
Figure 11.31a	The influence of the crude extracts, isolated compound and Amphotericin B (positive control) on the wound erythema of rat infected with <i>S. schenckii</i> .	253
Figure 11.31b	Average arbitrary values of erythema of rats infected with <i>S. schenckii</i> with error bars	254
Figure 11.32a	The influence of the crude extracts, isolated compound and Amphotericin B (positive control) on the exudate formed of rats infected with <i>C. albicans</i> .	255
Figure 11.32b	Average arbitrary values of exudate of rats infected with <i>C. albicans</i> with error bars	255
Figure 11.33a	The influence of the crude extracts, isolated compound and Amphotericin B (positive control) on the exudate formed of rats infected with <i>C. neoformans</i> .	256
Figure 11.33b	Average arbitrary values of exudate of rats infected with <i>C. neoformans</i> with error bars	256
Figure 11.34a	The influence of the crude extracts, isolated compound and Amphotericin B (positive control) on the exudate formed of rats infected with <i>M. canis</i> .	257
Figure 11.34b	Average arbitrary values of exudate of rats infected with <i>M. canis</i> with error bars	257
Figure 11.35a	The influence of the crude extracts, isolated compound and Amphotericin B (positive control) on the exudate formed of rats infected with <i>S. schenckii</i> .	258
Figure 11.35b	Average arbitrary values of exudate of rats infected with <i>S. schenckii</i> with error bars	258
Figure 11.36a	The influence of the crude extracts, isolated compound and	259

	Amphotericin B (positive control) on the crust formed of rats infected with <i>C. albicans</i> .	
Figure 11.36b	Average arbitrary values of crust formation of rats infected with <i>C. albicans</i> with error bars	260
Figure 11.37a	The influence of the crude extracts, isolated compound and Amphotericin B (positive control) on the crust formed of rats infected with <i>C. neoformans</i> .	260
Figure 11.37b	Average arbitrary values of crust formation of rats infected with <i>C. neoformans</i> with error bars	261
Figure 11.38a	The influence of the crude extracts, isolated compound and Amphotericin B (positive control) on the crust formed of rats infected with <i>M. canis</i> .	261
Figure 11.38b	Average arbitrary values of crust formation of rats infected with <i>M. canis</i> with error bars	262
Figure 11.39a	The influence of the crude extracts, isolated compound and Amphotericin B (positive control) on the crust formed of rats infected with <i>S. schenckii</i> .	262
Figure 11.39b	Average arbitrary values of crust formation of rats infected with <i>S. schenckii</i> with error bars	263
Figure 11.40	Effect of isolated compound on fungal pathogens.	263
Figure 11.41	Effect of amphotericin B on fungal pathogens.	264
Figure 11.42	Effect of <i>C. imberbe</i> acetone extract on fungal pathogens.	264
Figure 11.43	Effect of <i>C. nelsonii</i> acetone extract on fungal pathogens.	265
Figure 11.44	Effect of <i>C. albopunctatum</i> acetone extract on fungal pathogens.	265
Figure 11.45	Effect of <i>T. sericea</i> acetone extract on fungal pathogens.	266

LIST OF TABLES

Chapter 1		Page
Table 1.1	The Combretaceae family	7
Table 1.2	An overview of antifungal agents	15
 Chapter 2 		
Table 2.1	<i>Combretum</i> species collected for antifungal and antioxidant screening	47
Table 2.2	<i>Terminalia</i> species collected for antifungal and antioxidant screening	47
Table 2.3	The percentage mass (%) of <i>Terminalia</i> species extracted with four extractants from dried powdered leaves	50
Table 2.4	The percentage mass (%) of <i>Combretum</i> species extracted with four extractants from dried powdered leaves	50
 Chapter 3 		
Table 3.1	Qualitative DPPH assay on TLC of the 30 plants studied	68
Table 3.2	Number of antioxidant bands present in all <i>Combretum</i> species tested on EMW solvent systems and extractants	69
Table 3.3	Number of antioxidant bands present in all <i>Terminalia</i> species tested on EMW solvent systems and extractants	70
 Chapter 4 		
Table 4.1	Toxicity of different solvents on tested fungi	73
Table 4.2	MIC values and final % concentrations of different solvents against tested fungi	74
 Chapter 5 		
	<i>Terminalia</i> Paper	
	<i>Combretum</i> Paper	
 Chapter 6 		
	Bioautography papers	

Chapter 7

Table 7.1	Solvent mixtures used in column chromatography	158
Table 7.2	The mass (g) of <i>C. nelsonii</i> leaf powder extracted with four extractants from 502 g.	159
Table 7.3	Minimum Inhibitory Concentration (MIC) of <i>C. nelsonii</i> extracts after 24 H	160
Table 7.4	Total activity in ml/g of <i>C. nelsonii</i> extracts after 24 hours incubation at 37 °C	162
Table 7.5	The mass (g) of <i>C. nelsonii</i> acetone and DCM extracts isolated with different eluent systems	164

Chapter 9

Table 9.1	Results showing absorbance values at 540 nm for the various optimal extract concentration.	193
Table 9.2	Relative safety margin (using LC ₅₀ value from the brine shrimp assay and the MTT cytotoxicity assay) of the optimal extract.	197

Chapter 11

Table 11.1	Treatment in topical to study skin tolerance.	222
Table 11.2	Treatment of different rats in efficacy experiment	222
Table 11.3	Evaluation of erythema and exudate	223
Table 11.4	Treatment of different rats in efficacy experiment.	223
Table 11.5a	Quantitative histopathological findings of wounds of rats infected with <i>C. albicans</i> after topical application of different creams. (Pilot II)	239
Table 11.5b	Quantitative histopathological findings of wounds of rats infected with <i>C. neoformans</i> after topical application of different creams. (Pilot II)	240
Table 11.5c	Quantitative histopathological findings of wounds of rats infected with <i>M. canis</i> after topical application of different creams. (Pilot II)	241
Table 11.5d	Quantitative histopathological findings of wounds of rats infected with <i>S. schenckii</i> after topical application of different creams. (Pilot II)	242
Table 11.6a	Quantitative histopathological findings of wounds of rats infected with <i>C. albicans</i> after topical application of different	267

	creams. (Main Study)	
Table 11.6b	Quantitative histopathological findings of wounds of rats infected with <i>C. neoformans</i> after topical application of different creams. (Main Study)	268
Table 11.6c	Quantitative histopathological findings of wounds of rats infected with <i>M. canis</i> after topical application of different creams. (Main Study)	269
Table 11.6d	Quantitative histopathological findings of wounds of rats infected with <i>S. schenckii</i> after topical application of different creams. (Main Study)	270